CD BioGlyco offers cancer antigen 15-3 (CA 15-3) assays to monitor response to breast cancer treatment and to help observe breast cancer recurrence. We have the confidence to provide our clients with efficient, rapid and accurate biomarker detection services.

CA15–3

Breast cancer is the most common cancer among females and the second most common cancer in the world. Early detection of breast cancer can provide more treatment options and improved conditions for treatment or surgery. A variety of diagnostic techniques, including magnetic resonance imaging, positron emission tomography and biopsy, have been used to detect breast cancer. However, these strategies are expensive, time-consuming and cannot respond to large numbers of patients at the same time. Using serum biomarkers for cancer screening would be a desirable diagnostic technique to detect cancer through routine health examinations. In addition, such screening could improve the detection rate of early cancers and ultimately improve survival rates.

CA15-3 is a soluble form of MUC1, a transmembrane protein with variable numbers of tandem repeats of a glycosylation-modified peptide. Glycosylation changes of CA15-3 have great potential to reflect carcinogenesis, while most glycosylation assays involve highly purified glycoproteins and expensive procedures such as capillary electrophoresis, mass spectrometry (MS) and high-performance liquid chromatography (HPLC). Therefore, it is important to develop efficient, simple and low-cost assays to detect glycosylation in serum samples.

Our Strategies

CD BioGlyco has developed ultra-sensitive, simple and reliable strategies to detect glyco-biomarker CA15-3 for screening of early-stage or localized breast cancer. The strategies we provide include but are not limited to:

• Antibody lectin sandwich assay
  The immobilized anti-CA15-3 monoclonal antibody is used to capture CA15-3 in serum. Then, concanavalin A (ConA) lectin, which preferentially binds high mannose N-glycan, is used to detect the glycosylation of CA15-3. The strategy appears to be effective in discriminating against breast cancer from different stages.
• A sandwich-type electrochemical immunosensor
  This method has demonstrated excellent sensitivity and specificity in the detection of CA 15-3 in human serum and can be used as a powerful diagnostic tool for the clinical determination of CA 15-3 and other glyco-biomarkers.

CA15-3 Testing Services Support Cancer Research

We integrate advanced immunoassay tools, such as highly sensitive enzyme-linked immunosorbent assay (ELISA) and automated chemiluminescent immunoassay systems, for precise quantification of total CA15-3. To delve into the intricate glycosylation patterns, we utilize sophisticated MS techniques capable of identifying and quantifying individual glycan structures attached to the CA15-3 protein. Furthermore, we employ specialized glycan enrichment strategies and high-resolution chromatographic separations to ensure optimal sample preparation and data quality.

• Our service covers both quantitative measurement of total CA15-3 levels and in-depth qualitative and quantitative analysis of its glycosylation patterns.
• Whether your project requires high-throughput screening of large sample cohorts for biomarker discovery or detailed characterization of CA15-3 glycoforms for specific mechanistic studies, CD BioGlyco provides flexible and precise solutions.
• We are equipped to process a variety of biological sample types, including serum, plasma, and other relevant biofluids or tissue extracts.

Workflow

Applications

• Our highly sensitive analytical services can be used to identify novel glycan biomarkers and glycan profiles associated with CA15-3.
• Tracking changes in CA15-3 levels and their specific glycosylation patterns over time, it can be used to evaluate the effectiveness of different drugs.
• Our services can be used to investigate the fundamental biological role of CA15-3 glycosylation in tumor growth, metastasis, and immune evasion.

Advantages of Us

• Unlike standard CA15-3 tests that only provide total concentration, our service delivers in-depth glycoprofiling. This allows for the identification of subtle, yet critical, changes in glycosylation patterns that are often linked to disease progression or specific cancer subtypes.
• We employ advanced integrated technologies, including highly selective enrichment and sensitive MS, to achieve exceptional sensitivity and specificity in detecting CA15-3 and its glycoforms.
• CD BioGlyco offers customizable service options to accommodate diverse sample types, project scales, and specific analytical requirements, providing tailored solutions for your unique challenges.

Publication Data

Frequently Asked Questions

CD BioGlyco has established several strategies with significant analytical detection efficiency for CA15-3, with good specificity and sensitivity even in the presence of other proteins interference. If you need glyco-biomarker detection services, please contact us for further information.

Associated Services